Compare MMI & MDXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMI | MDXG |
|---|---|---|
| Founded | 1971 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2013 | N/A |
| Metric | MMI | MDXG |
|---|---|---|
| Price | $27.82 | $7.23 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $29.00 | $12.00 |
| AVG Volume (30 Days) | 364.5K | ★ 774.9K |
| Earning Date | 11-07-2025 | 10-29-2025 |
| Dividend Yield | ★ 1.78% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | ★ $751,284,000.00 | $393,442,000.00 |
| Revenue This Year | $11.94 | $19.13 |
| Revenue Next Year | $15.59 | $2.11 |
| P/E Ratio | ★ N/A | $26.73 |
| Revenue Growth | ★ 20.74 | 14.77 |
| 52 Week Low | $27.35 | $5.79 |
| 52 Week High | $41.94 | $9.71 |
| Indicator | MMI | MDXG |
|---|---|---|
| Relative Strength Index (RSI) | 36.79 | 56.44 |
| Support Level | $28.74 | $6.62 |
| Resistance Level | $29.65 | $7.06 |
| Average True Range (ATR) | 0.82 | 0.23 |
| MACD | -0.13 | 0.05 |
| Stochastic Oscillator | 13.28 | 91.11 |
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.